Alembic Pharmaceuticals Ltd

Alembic Pharmaceuticals Ltd Performance

₹485.7
Day's Price Range
₹498.95
₹476.05
52-Week Price Range
₹792.9
1 Month Return-5.22 %
3 Month Return-14.25 %
1 Year Return-32.52 %

Analyst Rating

based on 17 analysts

HOLD
29.41%
Buy
47.06%
Hold
23.53%
Sell

Based on 17 analysts offering long term price targets for Alembic Pharmaceuticals Ltd. An average target of ₹630.24

Source: S&P Global Market Intelligence

Analyst Forecast

Alembic Pharmaceuticals Ltd price forecast by 17 analysts

Upside of26.71%

High

₹944

Target

₹630.24

Low

₹550

Current Price: ₹489.65

Target Price: ₹630.24

Source: S&P Global Market Intelligence

Alembic Pharmaceuticals Ltd Price Movements

  • Alembic Pharma fell 2% on 13 Mar, 2023

    Alembic Pharma share price declined. However, US regulator inspections gave a clean chit in its Karakhadi facility.

  • Alembic Pharma fell 1% on 09 Mar, 2023

    Alembic Pharma declined 1% amid weakness in Pharma stocks. The pharma company's Brexpiprazole tablets received US regulator approval recently which capped the losses.

  • Alembic Pharmaceuticals fell 3% on 08 Mar, 2023

    Alembic Pharma share price fell amid weakness in Pharma stocks. Reports of the company getting US regulator's approval for hypertension treatment drug capped the losses.

  • Alembic Pharma jumped 5% on 06 Mar, 2023

    Alembic Pharma share price gained after the pharma major's injection for breast cancer received approval from the US regulator.

  • Alembic Pharma gained marginally on 03 Mar, 2023

    Alembic Pharma share price moved marginally higher. The company's board approved an impairment charge of Rs 1,150 crores for three Gujarat plants which capped gains.

  • Alembic Pharma dipped 1% on 01 Mar, 2023

    Alembic Pharma share price ended lower following the weakness in most Pharma stocks. Reports of Alembic Pharma receiving a final USFDA approval for cancer treatment injections capped the losses.

  • Alembic Pharma dropped 1% on 13 Feb, 2023

    Alembic Pharma share price declined to touch 52-week lows. Overall weakness in the pharma sector continued to hurt the stock.

Alembic Pharmaceuticals Ltd Valuation

Alembic Pharmaceuticals Ltd in the last 5 years

Lowest (11.53x)

March 23, 2020

Today (43.52x)

March 22, 2023

Highest (50.18x)

January 3, 2023

LowHigh

43.52x

Price to Earnings TTM Ratio

Insights on Alembic Pharmaceuticals Ltd

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    MF Holding Up
    img

    Mutual Funds have increased holdings from 5.36% to 5.87% in Dec 2022 quarter

  • imgPOSITIVE IMPACT

    Revenue Rich
    img

    Revenue is up for the last 3 quarters, 1.26KCr → 1.50KCr (in ₹), with an average increase of 8.3% per quarter

  • imgPOSITIVE IMPACT

    Retail Holding Up
    img

    Retail Investor have increased holdings from 12.53% to 12.65% in Dec 2022 quarter

  • imgNO EFFECT

    Against Peers
    img

    In the last 3 years, Sun Pharmaceuticals Industries Ltd has given 199.6% return, outperforming this stock by 187.9%

  • imgNO EFFECT

    Against Peers
    img

    In the last 1 year, Dr Reddys Laboratories Ltd has given 8.4% return, outperforming this stock by 40.9%

  • imgNO EFFECT

    Promoter Holding Unchanged
    img

    Promoters holdings remained unchanged at 69.61% of holdings in Dec 2022 quarter

  • imgNEGATIVE IMPACT

    Price Dip
    img

    In the last 1 year, APLLTD stock has moved down by -32.5%

  • imgNEGATIVE IMPACT

    FII Holding Down
    img

    Foreign Institutions have decreased holdings from 5.32% to 4.99% in Dec 2022 quarter

  • imgNEGATIVE IMPACT

    Profit Down
    img

    Netprofit is down for the last 2 quarters, 133.35Cr → 121.92Cr (in ₹), with an average decrease of 8.6% per quarter

Alembic Pharmaceuticals Ltd Shareholding Pattern

InvestorsHoldings %Prev. 4 periods3M change
Promoter Holdings
69.61%
0.00
Foreign Institutions
4.99%
-6.28
Mutual Funds
5.87%
9.53
Retail Investors
12.65%
0.96
Others
6.89%
-4.12

Alembic Pharmaceuticals Ltd Company Financials

  • Quarterly
  • Annual
Value in ₹ crore

Corporate Announcements

  • Alembic Pharmaceuticals Ltd Earnings Results

    Alembic Pharmaceuticals Ltd’s net profit fell -29.03% since last year same period to ₹121.92Cr in the Q3 2022-2023. On a quarterly growth basis, Alembic Pharmaceuticals Ltd has generated -8.57% fall in its net profits since last 3-months.

    Read More
  • Alembic Pharmaceuticals Ltd Dividends May,2022

    In the quarter ending June 2022, Alembic Pharmaceuticals Ltd has declared dividend of ₹10 - translating a dividend yield of 4.83%.

    Read More

Alembic Pharmaceuticals Ltd Company Information

Alembic Pharmaceuticals manufactures and markets generic pharmaceutical products all over the world. The companys state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the US FDA. The company is one of the leaders in branded generics in India. Alembic Pharmaceuticals Ltd was incorporated on June 16 2010 as a wholly owned subsidiary of Alembic Ltd. The company is engaged in pharmaceuticals business. As per the scheme of arrangement the Pharmaceutical Undertaking of the Alembic Ltd was demerged and transferred to the company with effect from appointed date April 1 2010. In April 15 2011 the company ceased to be a subsidiary of Alembic Ltd consequent to the allotment of 133515914 equity shares of Rs 2 each to the shareholders of Alembic Ltd as per the scheme of arrangement. The shareholding of Alembic Ltd in the company reduced from 100 to 29.18. Thus the company became an associate of Alembic Ltd.In September 20 2011 the equity shares of the company were listed on the Bombay Stock Exchange and National Stock Exchange. During 2012 Alembic and Breckenridge Announced Paragraph IV ANDA Litigation with Pfizer on Desvenlafaxine Pristiq. The company enters into a product development and license agreement with AccuBreak Pharmaceuticals Inc USA. During 2013 the company got USFDA approval for its NDA Desvenlafaxine Base Extended Release Tablets and also entered into an outlicensing agreement with Ranbaxy Pharmaceuticals Inc Ranbaxy to market its product in USA. During 2014 the company announces joint venture with Adwiya Mami SARL Algeria through its wholly owned Subsidiary Alembic Global Holding S.A..During 2015 the companys associate signs exclusive agreement with Novartis. During the year the company launched Aripiprazole on Day1. Also during the year the company transitioned to own marketing in the US.In 2016 the company formed 60:40 joint venture with Orbicular viz. Aleor Dermaceuitical Limited for developing Dermatology Products for international markets.In July 2017 Alembic Pharmaceuticals inaugurated a state of the art anticancer manufacturing facility at Panelav Halol Gujarat. The plant has an initial manufacturing capacity of 60 million tablets/capsules and approximate 20 million vials of liquid injectable and lyophilized concentrates. Alembic will commence exporting oncology products from the new plant to US Middle East North Africa Australia and South Africa. On 1 November 2017 Alembic Pharmaceuticals announced that through its 100 owned subsidiary Alembic Pharmaceuticals Inc. it has completed acquisition of West Caldwell New Jersey USA based generic drug developer Orit Laboratories LLC along with real estate owned by Okner Realty LLC. Orit has seven approved ANDAs and four ANDAs pending approval. With a stateoftheart 8600 square feet RD and pilot manufacturing facility Orit is focused on developing and filing oral solid and liquid products. Apart from existing ANDAs Orit adds complementary skill sets in soft gelatin based oral solids and oral liquids to Alembic with a team of eight highly experienced scientists. On 21 March 2018 Alembic Pharmaceuticals announced that the United States Food and Drug Administration US FDA conducted an inspection at the companys formulation facility located at Panelav Gujarat from 12 March to 20 March 2018. This was a scheduled inspection and at the end of the inspection the US FDA issued a Form 483 with 3 observations. None of the observations are related to data integrity or repetitive in nature. The company is preparing the response to the observations which will be submitted to the US FDA shortly. On 24 April 2018 Alembic Pharmaceuticals announced that the United States Food and Drug Administration US FDA conducted an inspection at Alembic Pharmaceuticals API Facility located at Panelav from 16 April 2018 to 23 April 2018. This was a scheduled inspection and at the end of the inspection there were zero 483s.In 2019 the Company launched 9 new products in the US.In 2021 Rhizens outlicenced novel molecule Umbralicib UKONIQ was launched by TG Therapeutics USA. During the year 202122 the Company acquired the balance 40 stake held by the joint venture partner in Aleor DermaceuticalsLimited Aleor and pursuant to said acquisition Aleor became a wholly owned subsidiary of the Company.The Board of Directors at their meeting held on 29th March 2022 approved the Scheme of Arrangement for Amalgamation of Aleor Dermaceuticals Limited wholly owned subsidiary with the Company and their respective shareholders with the Appointed Date 1st April 2021 which is now effective from 29th August 2022.

Alembic Pharmaceuticals Ltd Share Price: ₹489.65 per share as on 23 Mar, 2023 04:01 PM
Alembic Pharmaceuticals Ltd Market Capitalisation: ₹10,519.08Cr as of today
Alembic Pharmaceuticals Ltd Revenue: ₹1,509.46Cr as on December 2022 (Q4 22)
Alembic Pharmaceuticals Ltd Net Profit: ₹121.92Cr as on December 2022 (Q4 22)
Alembic Pharmaceuticals Ltd Listing date: 11 May, 2008
Alembic Pharmaceuticals Ltd Chairperson Name: Chirayu R Amin
OrganisationAlembic Pharmaceuticals Ltd
HeadquartersVadodara
IndustryPharmaceuticals
E-voting on sharesClick here to vote

Frequently Asked Questions

Alembic Pharmaceuticals Ltd(APLLTD) share price today is ₹489.65 (last updated 23 Mar, 2023 at 04:01 PM)

  • Today’s highest price of Alembic Pharmaceuticals Ltd(APLLTD) is ₹498.95.
  • Today’s lowest price of Alembic Pharmaceuticals Ltd(APLLTD) is ₹485.70.
  • (last updated 23 Mar, 2023 at 04:01 PM)
Today’s traded volume of Alembic Pharmaceuticals Ltd(APLLTD) is 47297.
Today’s market capitalisation of Alembic Pharmaceuticals Ltd(APLLTD) is ₹10,519.08Cr.
Alembic Pharmaceuticals Ltd(APLLTD)Price
52 Week High₹792.90
52 Week Low₹476.05
  • (last updated 23 Mar, 2023 at 04:01 PM)
  • Alembic Pharmaceuticals Ltd(APLLTD) share price is ₹489.65 (last updated 23 Mar, 2023 at 04:01 PM). It is down -38.25% from its 52 Week High price of ₹792.90
    Alembic Pharmaceuticals Ltd(APLLTD) share price is ₹489.65 (last updated 23 Mar, 2023 at 04:01 PM). It is up 2.86% from its 52 Week Low price of ₹476.05
    Alembic Pharmaceuticals Ltd(APLLTD)Returns (%)
    1 Day Returns-1.56%
    1 Month Returns-5.22%
    1 Year Returns-32.52%
    3 Year Returns11.67%
    5 Year Returns-6.64%
    Alembic Pharmaceuticals Ltd(APLLTD) share price is ₹489.65 and its price to earning (PE) is 43.52. A high PE ratio indicates that a share price is overvalued, or investors are expecting a high growth rate in the future.

    Indian stocks brokerage services are provided by INDmoney Private Limited. INDmoney Private Limited is carrying out the business of in respect to stock broking activities and also carries out the activities of depository participant. SEBI Registration No. INZ000305337 | SEBI Depository Participant Registration No. IN-DP-690-2022 Depository Participant ID: CDSL 12095500 | Trading and Clearing Member of NSE (90267, M70042) and BSE (6779)

    Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. The securities quoted are exemplary and not recommendatory. Past performance is not indicative of future returns.